23ANDME HOLDING CO.

Analyst Reco. 23andMe Holding Co.

Equities

ME

US90138Q1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
0.4976 ^USD	+2.26%		-0.92%	-45.53%

Apr. 24	23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting	CI
Apr. 23	Petros, Lemonaid Health Collaborate to Expand Stendra Availability	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

23andMe CEO Mulls Plan to Take Company Private	Apr. 18	MT
Citigroup Adjusts 23andMe Price Target to $0.47 From $0.85, Maintains Neutral Rating	Apr. 16	MT
Citigroup Adjusts 23andMe Holding's Price Target to $1.75 From $2.50, Keeps Buy Rating	23-08-10	MT
Citigroup Adjusts 23andMe Price Target to $2.50 From $3.75, Maintains Neutral Rating	23-05-26	MT
Berenberg Bank Initiates Coverage on 23andMe Holding With Buy Rating, $7 Price Target	22-11-29	MT
Credit Suisse Trims 23andMe Holding's Price Target to $6 From $7, Keeps Outperform Rating	22-11-08	MT
Cowen Initiates Coverage on 23andMe With Outperform Rating, $6 Price Target	22-09-22	MT
Credit Suisse Lowers 23andMe Holding's Price Target to $7 from $11, Notes Near-Term Consumer Volatility; Keeps Outperform Rating	22-05-27	MT
Citigroup Adjusts Price Target on 23andMe to $3 From $6, Maintains Neutral Rating	22-05-27	MT
Credit Suisse Lowers 23andMe Holding's PT to $11 from $14, Trims Revenue Multiple to Reflect Comparable Decline in Comps; Keeps Outperform Rating	22-02-11	MT
Citigroup Adjusts Price Target on 23andMe Holding to $9 From $13, Maintains Neutral Rating	21-12-20	MT
Citigroup Downgrades 23andMe to Neutral From Buy, Adjusts Price Target to $13 From $12	21-11-15	MT
CORRECTION : Credit Suisse Starts 23andMe Holding at Outperform with $13 PT	21-08-17	MT
23andMe : Shares Soar After Credit Suisse Initiates Coverage with Outperform Rating	21-08-17	MT
23ANDME : Credit Suisse Starts 23andMe Holding at Outperform with $31 PT, Sees Optionality for Therapeutics Segment Long Term; Trading Lower Pre-Market	21-08-17	MT
23ANDME : Citigroup Starts 23andMe Holding at Buy with $14 Price Target	21-07-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Anne Wojcicki, CEO of 23andMe: partnership with Amazon and cancer treatment results

INTERVIEW - Anne Wojcicki, CEO of 23andMe: partnership with Amazon and cancer treatment results

July 13, 2023 at 02:26 pm EDT

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW